Scholarlink

Introduction <p>Amyloid- and tau-positron emission tomography (PET) are promising modalities for detecting pathological changes associated with Alzheimer’s disease (AD); however, their application is limited. Although the use of cerebrospinal fluid (CSF) biomarkers as alternatives to amyloid-PET and tau-PET has been explored, no in vitro diagnostic-approved or commercial CSF biomarker assays are currently available for detecting tau pathology in clinical practice.</p> Methods <p>In this study, we determined and validated the optimal cutoff value for the ratio of tau phosphorylated at a threonine residue at position 181 (pTau<sub>181</sub>) to β-amyloid(1–42) (Aβ<sub>42</sub>) in CSF, measured with the Elecsys<sup>®</sup> Phospho-Tau (181P) CSF and β-Amyloid(1–42) CSF immunoassays (Roche Diagnostics International Ltd, Rotkreuz, Switzerland), based on its concordance with binary tau-PET status. Clinical performance was explored using CSF measurements and tau-PET scans retrospectively obtained from a subset of subjects with mild cognitive impairment and dementia due to AD in two independent cohorts, Alzheimer’s Disease Neuroimaging Initiative-2/3 (ADNI-2/3; <i>N</i> = 133) and Swedish BioFINDER-2 (<i>N</i> = 62).</p> Results <p>In the first part of this analysis (ADNI-2/3 pre-analytics), a CSF pTau<sub>181</sub>/Aβ<sub>42</sub> cutoff value of 0.0395 was selected as the best compromise between positive percent agreement (PPA) and negative percent agreement (NPA) for the tau-PET visual read endpoint. After adjustment to account for differences between the ADNI-specific protocol and the manufacturer’s recommended pre-analytical protocol used in BioFINDER-2, the optimal CSF pTau<sub>181</sub>/Aβ<sub>42</sub> cutoff value was set at 0.037. The adjusted cutoff was validated in BioFINDER-2 and was associated with a PPA of 85.7% (95% confidence interval [CI] 70.6, 93.7), NPA of 70.4% (95%&#xa0;CI 51.5, 84.1), and overall percent agreement (OPA) of 79.0% (95%&#xa0;CI 67.4, 87.3); the positive and negative likelihood ratios were 2.89 and 0.203, respectively.</p> Conclusion <p>The Elecsys CSF pTau<sub>181</sub>/Aβ<sub>42</sub> ratio may be a reliable tool for identifying tau pathology in clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical Performance of the Elecsys CSF pTau181/Aβ42 Ratio for Concordance with Tau-PET in Two Independent Cohorts

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月20日

查看全文
  • Ruben Smith,
  • Leslie Shaw,
  • Sebastian Palmqvist,
  • Niklas Mattsson-Carlgren,
  • Gregory Klein,
  • Matteo Tonietto,
  • Clara Quijano-Rubio,
  • Christopher M. Rank,
  • Myrto Andreadou,
  • Samantha C. Burnham,
  • Erik Stomrud

摘要

Introduction

Amyloid- and tau-positron emission tomography (PET) are promising modalities for detecting pathological changes associated with Alzheimer’s disease (AD); however, their application is limited. Although the use of cerebrospinal fluid (CSF) biomarkers as alternatives to amyloid-PET and tau-PET has been explored, no in vitro diagnostic-approved or commercial CSF biomarker assays are currently available for detecting tau pathology in clinical practice.

Methods

In this study, we determined and validated the optimal cutoff value for the ratio of tau phosphorylated at a threonine residue at position 181 (pTau181) to β-amyloid(1–42) (Aβ42) in CSF, measured with the Elecsys® Phospho-Tau (181P) CSF and β-Amyloid(1–42) CSF immunoassays (Roche Diagnostics International Ltd, Rotkreuz, Switzerland), based on its concordance with binary tau-PET status. Clinical performance was explored using CSF measurements and tau-PET scans retrospectively obtained from a subset of subjects with mild cognitive impairment and dementia due to AD in two independent cohorts, Alzheimer’s Disease Neuroimaging Initiative-2/3 (ADNI-2/3; N = 133) and Swedish BioFINDER-2 (N = 62).

Results

In the first part of this analysis (ADNI-2/3 pre-analytics), a CSF pTau181/Aβ42 cutoff value of 0.0395 was selected as the best compromise between positive percent agreement (PPA) and negative percent agreement (NPA) for the tau-PET visual read endpoint. After adjustment to account for differences between the ADNI-specific protocol and the manufacturer’s recommended pre-analytical protocol used in BioFINDER-2, the optimal CSF pTau181/Aβ42 cutoff value was set at 0.037. The adjusted cutoff was validated in BioFINDER-2 and was associated with a PPA of 85.7% (95% confidence interval [CI] 70.6, 93.7), NPA of 70.4% (95% CI 51.5, 84.1), and overall percent agreement (OPA) of 79.0% (95% CI 67.4, 87.3); the positive and negative likelihood ratios were 2.89 and 0.203, respectively.

Conclusion

The Elecsys CSF pTau181/Aβ42 ratio may be a reliable tool for identifying tau pathology in clinical practice.